Wet AMD

>

Latest News

AAO 2023: Adverum Biotechnologies unveils 3-Year efficacy, safety results from OPTIC extension study in patients with wet AMD
AAO 2023: Adverum Biotechnologies unveils 3-Year efficacy, safety results from OPTIC extension study in patients with wet AMD

November 5th 2023

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco.

Image credit: ©MargJohnsonVA – stock.adobe.com
Vitreous Retina Macula Consultants of New York (VRMNY) to participate in a wet AMD study with Regenxbio

October 19th 2023

Retina Society 2023: A comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib, and sunitinib
Retina Society 2023: A comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib, and sunitinib

October 16th 2023

Image credit: ©gopixa– stock.adobe.com
UC Davis researchers administer Phase 3 ABBV-RGX-314, a gene therapy treatment for wet AMD

September 5th 2023

Image credit: ©Araki Illustrations – stock.adobe.com
BREAKING: FDA issues CRL for Outlook Therapeutics’ ONS-5010

August 30th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.